AU5215700A - Substituted indolinone as tyrosine kinase inhibitors - Google Patents

Substituted indolinone as tyrosine kinase inhibitors

Info

Publication number
AU5215700A
AU5215700A AU52157/00A AU5215700A AU5215700A AU 5215700 A AU5215700 A AU 5215700A AU 52157/00 A AU52157/00 A AU 52157/00A AU 5215700 A AU5215700 A AU 5215700A AU 5215700 A AU5215700 A AU 5215700A
Authority
AU
Australia
Prior art keywords
tyrosine kinase
kinase inhibitors
substituted indolinone
indolinone
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52157/00A
Other languages
English (en)
Inventor
Armin Heckel
Norbert Redemann
Gerald Roth
Walter Spevak
Ulrike Tontsch-Grunt
Jacobus C. A. Van Meel
Rainer Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU5215700A publication Critical patent/AU5215700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU52157/00A 1999-05-27 2000-05-23 Substituted indolinone as tyrosine kinase inhibitors Abandoned AU5215700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19924401 1999-05-27
DE19924401A DE19924401A1 (de) 1999-05-27 1999-05-27 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/004685 WO2000073297A1 (de) 1999-05-27 2000-05-23 Substituierte indolinone als tyrosinkinase inhibitoren

Publications (1)

Publication Number Publication Date
AU5215700A true AU5215700A (en) 2000-12-18

Family

ID=7909416

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52157/00A Abandoned AU5215700A (en) 1999-05-27 2000-05-23 Substituted indolinone as tyrosine kinase inhibitors

Country Status (3)

Country Link
AU (1) AU5215700A (de)
DE (1) DE19924401A1 (de)
WO (1) WO2000073297A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
DE60223063T2 (de) 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
WO2003035049A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
DE10147088A1 (de) * 2001-09-25 2003-04-17 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Erkrankungen, die mit Zellwachstumsstörungen einhergehen und Testsystem zum Auffinden solcher Wirksubstanzen
US7005444B2 (en) 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
US6686362B2 (en) 2001-12-27 2004-02-03 Theravance, Inc. Indolinone derivatives
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
CA2731919A1 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh New compounds
EP2837626A1 (de) * 2013-08-16 2015-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Indolinon-Derivate als GRK5-Modulatoren
EP3056202A1 (de) * 2015-02-16 2016-08-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzopyrrolidone-derivate mit antiviralen und antitumor-eigenschaften

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2000073297A1 (de) 2000-12-07
DE19924401A1 (de) 2000-11-30

Similar Documents

Publication Publication Date Title
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU2001288374A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
HK1049154A1 (zh) 作為酪氨酸激酶抑制劑的2-吡唑啉-5-酮
AU2002303892A1 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
EG24381A (en) Tyrosine kinase inhibitors
AU3770000A (en) Indolinone compounds as kinase inhibitors
AU6471300A (en) P38map kinase inhibitors
EP1161433A4 (de) Tyrosin-kinase-inhibitoren
AU2003299651A1 (en) Tyrosine kinase inhibitors
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
HK1053644A1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2003298942A1 (en) Tyrosine kinase inhibitors
AU5215700A (en) Substituted indolinone as tyrosine kinase inhibitors
AU2003275282A1 (en) Novel tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU3703499A (en) Substituted indolinones as kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2001241917A1 (en) Myt1 kinase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase